Tezepelumab demonstrated rapid and sustained clinical improvements in nasal polyp burden and symptom control, with effects ...

Discover 10 causes of nasal breathing difficulties from deviated septum to spray addiction, plus effective solutions for ...

Blood basophils among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) may indicate the degree of inflammation, according to findings published in the European Archives of ...

As flowers bloom and temperatures climb, spring brings in allergy season for many. When sneezing, itchy eyes or sinus ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Q1 2025 Earnings Call Transcript May 8, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.42 EPS, ...

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025: Cambridge, UK Wednesday, May 14, 2025, 13:0 ...

In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

Asthma and Antibiotic Use May Predict Nasal Polyp Recurrence After Endoscopic ... and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...